Ductal Carcinoma In Situ Treatment in Malaysia
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Ductal Carcinoma In Situ?
Ductal carcinoma in situ is an extremely early form of breast cancer. When it occurs, the cancer cells are contained within a breast milk duct, and the breast tissue is still free of cancerous cells. A common term for this type of breast cancer is DCIS. This type of breast cancer is sometimes referred to as stage 0, noninvasive, or preinvasive.
DCIS is usually found on a mammogram that is done to screen for breast cancer or to investigate a bulge in the breast. There is a minimal chance that DCIS will become invasive and threaten life. However, it must be evaluated, and treatment options must be considered.
DCIS is often treated with surgery. Other treatments may include hormone therapy or radiation therapy in addition to surgery.
What is the Importance of Timely Treatment?
Ductal Cell Carcinoma in Situ (DCIS) must be treated early to lower the chance of recurrence and spread to other body areas, as well as to stop it from developing into invasive breast cancer. Early detection reduces the psychological and physical effects of more invasive surgeries, increases survival rates, and permits breast-conserving therapy. Patients who receive immediate treatment for DCIS have a better prognosis and a higher quality of life, and their chances of the disease developing into something invasive or life-threatening are significantly decreased.
What are the Common Symptoms of Ductal Carcinoma In situ?
Usually, there are no symptoms associated with ductal carcinoma in situ. DCIS is another name for this early stage of breast cancer.
DCIS can occasionally result in symptoms like:
- A lump in the breast.
- Bloody discharge from the nipples.
DCIS is typically detected during mammography. In breast tissue, it manifests as microscopic calcium particles, which are calcifications, deposits of calcium.
Causes and Risk Factors of Ductal Carcinoma In Situ
Causes
- A non-malignant breast cancer that starts in the milk ducts is referred to as ductal carcinoma in situ (DCIS). While their exact cause is not known, risk factors are age (typically greater than 50), radiation, family history or genetic defects (e.g., BRCA1/2), hormonal imbalances, and personal history of benign breast disease.
- The risk can also be increased by lifestyle factors such as obesity, alcohol consumption, and lack of exercise, as well as previous reproductive history. Early detection screening is key to the management of DCIS.
Risk Factors
- Age
- Hormonal Factors
- History & Genetics
- Personal History of Breast Conditions
- Radiation Exposure
- Obesity
Connect with our advisor for a PRIORITY response
Latest Research and Technologies in the Treatment of Ductal Carcinoma In Situ in Malaysia
In recent years, Malaysia has researched new treatments for ductal carcinoma in situ (DCIS), focusing on local drug delivery methods. One possible approach is applying nanocarriers to deliver medication intraductally to the affected mammary ducts directly. This method might reduce systemic side effects through heightened medication specificity and enhance DCIS patients' treatment outcomes. These advancements, which are under investigation now, are promising for more personalised and effective therapies in the future.
Treatment options for Ductal Carcinoma In Situ
Lumpectomy: The breast cancer and a portion of the surrounding normal tissue are cut out during a lumpectomy. There is no removal of the rest of the breast tissue. Wide local excision and breast-conserving surgery are alternative names for this procedure. Most patients who have a lumpectomy also undergo radiation therapy.
Mastectomy: The removal of all the breast tissue by operation is called a mastectomy. If you prefer, breast reconstruction to re-form the appearance of the breast may be performed at the same time or later on.
Cost Start From USD 3000 - USD 10000Explore Options
Hormone therapy: Endocrine therapy, also referred to as hormone therapy, involves using drugs that prevent the body from making specific hormones. It is applied in the treatment of breast cancers that are estrogen and progesterone-sensitive.
Cost Start From USD 1000 - USD 5000Explore Options
Radiation Therapy: To reduce the risk of recurrence, radiation therapy is often given after surgery for ductal carcinoma in situ (DCIS). It is typically recommended following a lumpectomy, especially if the tumour is large or has high-risk features. High-energy X-rays are employed in the treatment to locate and kill any remaining cancer cells in the breast tissue. Radiation therapy significantly decreases the possibility that DCIS could recur.
- Mammography is the most common screening method for detecting breast calcifications that may indicate DCIS.
- Breast ultrasound is often used together with mammography to evaluate areas of concern further.
- MRI: Provides high-resolution images and helps to determine the extent of DCIS.
- Biopsy: The best test for diagnosing DCIS is a biopsy, in which tissue is removed from the suspicious region to determine whether cancer cells are present.
MediRehab (a chain of rehabilitation centres—part of MediGence) provides comprehensive rehabilitation services to support patients through Teleconsultations and online therapy sessions.
- Physical Therapy assists in the recovery of strength, improvement in mobility, and removal of any restrictions after surgery (e.g., mastectomy or lumpectomy).
- Lymphedema Management: Physical therapists can attempt to reduce arm or breast swelling in patients receiving radiation therapy or surgery.
- Depending on the severity of the condition, your healthcare professional may prescribe medicine to help control your symptoms and support the treatment plan.
Instantly Connect with our Specialists
Hospitals for Ductal Carcinoma In Situ in Malaysia
Sunway Medical Centre
Kuala Lumpur, Malaysia
Sunway Medical Centre has initiated a comprehensive expansion plan close to its current hospital facility to enhance its ability to provide services to the global market. The new Cancer Radiosurgery Center and Nuclear Medicine Center, which will also house additional Centers of Excellence like the Digestive Health Center and Dialysis Center, marked the completion of Tower C's first phase in October 2016.
Ara Damansara Medical Centre
Kuala Lumpur, Malaysia
Situated at the junction of Petaling Jaya and Shah Alam, close to the Oasis Ara, Ara Damansara Medical Centre boasts a serene, luxurious ambiance.
The Centre has been awarded several prestigious awards such as the Global Health Asia Pacific Awards 2023, Newsweek Best Specialized Hospital APAC 2023, Healthcare Asia Awards 2023, and Malaysian Healthcare Wellness Excellence.
Prince Court Medical Centre
Kuala Lumpur, Malaysia
Prince Court is a private medical facility in the center of Kuala Lumpur that has 277 individual beds. Our dedication is to provide you with the best treatment possible from the time you arrive until you depart, healthier and happier. We are well-known for our top-notch facilities, cutting-edge technology, and friendly customer service.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Malaysia for Duct Carcinoma In Situ Treatment?
Malaysia is an excellent destination for treating Duct Carcinoma In Situ (DCIS) due to its world-class medical infrastructure, highly trained medical professionals, and access to the latest technologies. The country offers comprehensive care tailored to each patient's requirements, such as radiation therapy, surgery, and targeted therapies. Malaysia is also a favoured destination for high-value care because medical care costs are often lower than in other countries.
Frequently Asked Questions
Yes, mammography can often detect ductal carcinoma in situ (DCIS). DCIS usually appears as microcalcifications, microscopic calcium deposits that appear as white specks on X-rays. Microcalcifications can also occur with benign conditions, but when they occur in specific patterns, they can be a marker for DCIS. Mammograms are a key early detection method for DCIS, often before symptoms develop.
In Malaysia, a biopsy is the gold standard for diagnosing ductal carcinoma in situ (DCIS). While mammograms and other imaging tests can identify problematic spots, a biopsy is necessary to collect a tissue sample for microscopic analysis. Doctors can use this to effectively diagnose DCIS, evaluate its features, and choose the best course of treatment.
In Malaysia, ductal carcinoma in situ (DCIS) often needs surgery, although this depends on the individual case. Based on the size, location, and other features of the DCIS, the most frequent surgical options are mastectomy (breast removal) or lumpectomy (tumour removal).
Surgery is not always needed for DCIS, especially if the issue is detected early and can be treated with hormone therapy or radiation. After consultation with the medical team, the choice is made according to the patient's condition and personal preferences.
Mastectomy can be suggested for Ductal Carcinoma In Situ (DCIS) in Malaysia if the DCIS is large or widespread or if it occurs in several locations within the breast so that breast-conserving surgery, such as lumpectomy, is not as effective. It can also be suggested if the patient is at high risk of recurrence or if prior surgery has not worked to remove the cancer.
Radiation therapy is often recommended in Malaysia’s healthcare environments for ductal carcinoma in situ (DCIS), particularly after a lumpectomy. It targets any remaining breast cancer cells, reducing the risk of recurrence. However, radiation therapy is not required for all DCIS patients. Tumour size, margins, grade, and other risk factors affect the decision.
Ductal carcinoma in situ (DCIS) may recur after treatment in Malaysian patients; the risk is low if proper treatment is undertaken. The opposite or the same breast (local recurrence) can suffer from recurrence. Several factors, such as the grade of DCIS, the surgical margins, the application of radiation therapy, and the patient's overall condition, can influence the risk of recurrence. Imaging tests, monitoring, and follow-up treatment are essential in detecting early recurrence.
In Malaysia, women with Duct Carcinoma In Situ (DCIS), a non-invasive type of breast cancer, tend to have good survival rates. For most women, good outcomes are possible with early detection and good treatment, such as hormone therapy, radiation, and surgery. Improved survival rates for women with DCIS are attributed to Malaysia's well-equipped medical facilities and availability of the latest cancer treatments.
Yes, you can get a second opinion on Ductal Cell Carcinoma treatment in Malaysia through MediGence. With MediGence, you can connect with highly experienced professionals from top Malaysian hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from the best Malaysian hospitals. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.